Michael Sneed - Johnson Johnson President

JNJ Stock  USD 157.96  2.19  1.41%   

President

Mr. Michael E Sneed is the Executive Vice President Global Corporationrationrate Affairs and Chief Communication Officer of the Company. He joined the Company in 1986 as Product Director for Personal Products, a subsidiary of the Company, and gained increased responsibilities in executive positions across the global enterprise. In 2004, Mr. Sneed was appointed Company Group Chairman, Consumer North America, followed by Company Group Chairman, Vision Care Franchise in 2007. In 2012, he became the Vice President, Global Corporationrationrate Affairs and Chief Communications Officer since 2018.
Age 60
Tenure 6 years
Address One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
Phone732 524 0400
Webhttps://www.jnj.com
Sneed was appointed Executive Vice President, Global Corporationrationrationrate Affairs and Chief Communications Officer in January 2018, and became a member of the Executive Committee in July 2018, leading the corporation global marketing, communication, design and philanthropy functions.

Johnson Johnson Management Efficiency

The company has Return on Asset of 0.0833 % which means that on every $100 spent on assets, it made $0.0833 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1831 %, implying that it generated $0.1831 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to hike to 0.26 this year. Return On Assets is expected to hike to 0.13 this year. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 175.9 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).
The company has 30.43 B in debt with debt to equity (D/E) ratio of 0.43, which is OK given its current industry classification. Johnson Johnson has a current ratio of 1.4, which is typical for the industry and considered as normal. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Michael TangAgilent Technologies
50
Henrik AncherJensenAgilent Technologies
59
Rodney GonsalvesAgilent Technologies
58
Michele TrucksisSeres Therapeutics
64
Patrick KaltenbachAgilent Technologies
53
Wael HashadSeres Therapeutics
N/A
Bruce CFAEquillium
58
Dominique GrauAgilent Technologies
65
Jacob ThaysenAgilent Technologies
49
Thomas DesRosierSeres Therapeutics
63
Wendy RiederMadrigal Pharmaceuticals
46
Samraat RahaAgilent Technologies
51
Alicia RodriguezAgilent Technologies
N/A
Craig PhilipsKineta Inc
63
Marcus ChapmanSeres Therapeutics
47
Kevin HorganSeres Therapeutics
58
Robert McMahonAgilent Technologies
55
Mark DoakAgilent Technologies
63
Marc SchneebaumMadrigal Pharmaceuticals
64
Bruce SteelEquillium
50
Rebecca TaubMadrigal Pharmaceuticals
66
Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 141700 people. Johnson Johnson (JNJ) is traded on New York Stock Exchange in USA. It is located in One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 and employs 131,900 people. Johnson Johnson is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Duane Arsdale, Treasurer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Jasmina Brooks, President Webster
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Nadja West, Independent Director
Mark Larkins, Worldwide Secretary
Vanessa Broadhurst, Executive Vice President Global Corporate Affairs
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Tom Cavanaugh, Company Medicine
D Davis, Independent Director
Anne Mulcahy, Lead Independent Director
Ian Davis, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Mark Weinberger, Independent Director
A Washington, Independent Director
Dirk Brinckman, Chief Officer
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Joseph CPA, Executive CFO
Michael Bodner, Global Recovery
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Mary Beckerle, Independent Director
Darius Adamczyk, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Hani Abouhalka, Company Digital
Ahmet Tezel, Group RD
Robert Decker, Controller Officer
Mathai Mammen, Executive Vice President Pharmaceuticals, R&D
Timothy Schmid, Executive MedTech
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer
James Swanson, Executive Vice President, Chief Information Officer
Hubert Joly, Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health
Jessica Moore, Vice Relations
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Celine Martin, Group CSS
Eugene Washington, Independent Director
Elizabeth Forminard, Executive Counsel
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Guy MD, Group EMEA
Susan Lindquist, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Johnson Stock analysis

When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Johnson Johnson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.106
Dividend Share
4.7
Earnings Share
5.2
Revenue Per Share
33.613
Quarterly Revenue Growth
0.073
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.